(HealthDay News) – For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.

Pascale Fouqueray, MD, of Poxel in Lyon, France, and colleagues conducted a 12-week, Phase 2, randomized, controlled study involving 156 patients with type 2 diabetes who were inadequately controlled on metformin alone to assess the efficacy and safety of imeglimin as add-on therapy. Patients received a stable dose of metformin (1,500–2,000mg/day) plus imeglimin (1,500mg twice daily) or placebo.

After 12 weeks, the researchers found that the placebo-subtracted decrease in hemoglobin A1c was a significant −0.44% with metformin-imeglimin. Compared with metformin-placebo, metformin-imeglimin correlated with significant improvements in fasting plasma glucose and the proinsulin/insulin ratio from baseline. The safety profile of the metformin-imeglimin combination was similar to that of metformin-placebo, and the combination was generally well tolerated.

“This Phase 2 study demonstrated that first-in-class imeglimin was well tolerated and effective when combined with metformin as a potential new treatment for type 2 diabetes,” the authors write.


Continue Reading

Several authors disclosed financial ties to pharmaceutical companies, including Poxel, which primarily funded the study and manufactures imeglimin.

Abstract
Full Text (subscription or payment may be required)